Tagrisso 80 mg (Per Box)

Tagrisso 80 mg (Osimertinib) is a third-generation EGFR tyrosine kinase inhibitor designed for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It works by irreversibly blocking mutant EGFR proteins, inhibiting cancer cell growth while sparing normal cells.

This pharmaceutical-grade tablet is suitable for physician-supervised targeted therapy in advanced or metastatic NSCLC.

Uses of Tagrisso 80 mg

Approved Uses

• Treatment of EGFR T790M mutation-positive NSCLC

• First-line therapy for advanced NSCLC with EGFR mutations

• Management of metastatic or recurrent NSCLC

Investigational / Off-Label Uses

• Certain brain metastases in NSCLC patients

• Research-based EGFR-targeted therapy protocols

Mechanism of Action

Tagrisso 80 mg selectively and irreversibly inhibits EGFR T790M and other activating mutations, blocking abnormal signaling pathways that drive cancer cell proliferation. This leads to apoptosis and tumor growth reduction.

Dosage & Administration

• Typical adult dose: 80 mg orally once daily, or as prescribed

• Take with or without food

• Dose adjustments may be required based on side effects or liver function

Common Side Effects

• Diarrhea

• Rash or dry skin

• Fatigue

• Nausea

Serious Side Effects

• Severe heart rhythm changes (QT prolongation)

• Interstitial lung disease or pneumonitis

• Liver toxicity

• Severe allergic reactions

Drug Interactions

• CYP3A4 inducers or inhibitors may affect Osimertinib levels

• Avoid concomitant use with strong CYP3A modulators unless guided by a physician

• Consult a doctor before combining with other medications

Food & Lifestyle Interactions

• Can be taken with or without meals

• Avoid grapefruit and grapefruit juice

• Regular monitoring of liver and heart function is recommended

Monitoring & Tests

• Liver function tests

• ECG for QT interval monitoring

• Regular imaging for tumor response

• Physician monitoring for adverse effects

Precautions & Warnings

• Use only under physician supervision

• Not recommended during pregnancy or breastfeeding without guidance

• Caution in patients with heart or liver conditions

• Report any shortness of breath, persistent cough, or unusual swelling immediately